Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:01:15 EDT Sun 29 Jun 2025
Enter Symbol
or Name
USA
CA



Q:MNOV - MEDICINOVA INC - https://www.medicinova.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNOV - Q0.11.15·1.490.11.33+0.032.316.018981.29  1.33  1.282.55  1.1216:00:02Apr 1415 min RT 2¢

Recent Trades - Last 10 of 98
Time ETExPriceChangeVolume
16:00:02Q1.330.031,644
16:00:02Q1.330.03922
16:00:02Q1.330.0319
16:00:02Q1.330.031,465
16:00:02Q1.330.0337
16:00:02Q1.330.034,110
15:59:49Q1.330.03523
15:59:44Q1.330.03475
15:59:43Q1.3250.025100
15:59:41Q1.320.02165

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-04-14 19:00U:MNOVNews ReleaseMediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025
2025-04-08 19:00U:MNOVNews ReleaseFirst Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
2024-12-05 18:00U:MNOVNews ReleaseMediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
2024-11-19 09:00U:MNOVNews ReleaseMediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
2024-11-14 18:00U:MNOVNews ReleaseMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
2024-11-11 18:00U:MNOVNews ReleaseMediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
2024-10-23 19:00U:MNOVNews ReleaseMediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
2024-09-30 09:00U:MNOVNews ReleaseMediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
2024-09-09 19:00U:MNOVNews ReleaseMediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
2024-09-03 19:00U:MNOVNews ReleaseMediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
2024-08-29 19:00U:MNOVNews ReleaseMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition